Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis
Rituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis is a condition that can be expected. Thirty-fo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2024-10-01
|
| Series: | Gazi Medical Journal |
| Subjects: | |
| Online Access: | https://gazimedj.com/articles/transition-of-thyroid-autoantibodies-by-rituximab-treatment-in-women-with-rheumatoid-arthritis/doi/gmj.2024.4237 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526725229412352 |
|---|---|
| author | Hüseyin Demirci Ebru Aydoğan Bilge Ceydilek |
| author_facet | Hüseyin Demirci Ebru Aydoğan Bilge Ceydilek |
| author_sort | Hüseyin Demirci |
| collection | DOAJ |
| description | Rituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis is a condition that can be expected. Thirty-four-year-old female patient with rheumatoid arthritis received disease-modifying agents in various combinations for 9 years. Due to unresponsiveness to treatment, the biological agent rituximab was initiated. The patient also had euthyroided Hashimoto’s thyroiditis and nodular goiter for 15 years. At the time of the diagnosis of Hashimoto thyroiditis, anti-thyroid peroxidase (anti-TPO): 45 IU/mL (0-35), anti-thyroglobulin (anti-Tg) >3000 IU/mL (0-115) but after 4 cycles of treatment with rituximab anti-TPO: 7.38 U/mL (0-35), anti-Tg <10 U/mL (0-115). According to the literature; in patients treated with rituximab for thyroid MALT lymphoma, rheumatoid arthritis, and Grave’s disease, few have been reported to have declined levels of thyroid autoantibodies. The levothyroxine replacement dose decreased in some of these patients. The decline in thyroid antibodies with the treatment of rituximab reveals the hope that Hashimoto’s thyroiditis may be treatable. To understand the effect of rituximab treatment on the pathogenesis of Hashimoto's disease further studies involving a large series is required. |
| format | Article |
| id | doaj-art-0b7024e168e140fe88c3c6016cb93c9b |
| institution | Kabale University |
| issn | 2147-2092 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Gazi Medical Journal |
| spelling | doaj-art-0b7024e168e140fe88c3c6016cb93c9b2025-01-16T11:31:36ZengGalenos Publishing HouseGazi Medical Journal2147-20922024-10-0135444945110.12996/gmj.2024.4237Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid ArthritisHüseyin Demirci0https://orcid.org/0000-0003-0737-2360Ebru Aydoğan1https://orcid.org/0009-0005-7939-742XBilge Ceydilek2https://orcid.org/0000-0002-7312-1343Clinic of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, TürkiyeDepartment of Occupational Medicine, Hacettepe University Hospitals, Ankara, TürkiyeClinic of Endocrinology and Metabolism, Acıbadem International Hospital, Ankara, TürkiyeRituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis is a condition that can be expected. Thirty-four-year-old female patient with rheumatoid arthritis received disease-modifying agents in various combinations for 9 years. Due to unresponsiveness to treatment, the biological agent rituximab was initiated. The patient also had euthyroided Hashimoto’s thyroiditis and nodular goiter for 15 years. At the time of the diagnosis of Hashimoto thyroiditis, anti-thyroid peroxidase (anti-TPO): 45 IU/mL (0-35), anti-thyroglobulin (anti-Tg) >3000 IU/mL (0-115) but after 4 cycles of treatment with rituximab anti-TPO: 7.38 U/mL (0-35), anti-Tg <10 U/mL (0-115). According to the literature; in patients treated with rituximab for thyroid MALT lymphoma, rheumatoid arthritis, and Grave’s disease, few have been reported to have declined levels of thyroid autoantibodies. The levothyroxine replacement dose decreased in some of these patients. The decline in thyroid antibodies with the treatment of rituximab reveals the hope that Hashimoto’s thyroiditis may be treatable. To understand the effect of rituximab treatment on the pathogenesis of Hashimoto's disease further studies involving a large series is required.https://gazimedj.com/articles/transition-of-thyroid-autoantibodies-by-rituximab-treatment-in-women-with-rheumatoid-arthritis/doi/gmj.2024.4237hashimoto’s thyroiditisautoimmune thyroiditisrituximab |
| spellingShingle | Hüseyin Demirci Ebru Aydoğan Bilge Ceydilek Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis Gazi Medical Journal hashimoto’s thyroiditis autoimmune thyroiditis rituximab |
| title | Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis |
| title_full | Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis |
| title_fullStr | Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis |
| title_full_unstemmed | Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis |
| title_short | Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis |
| title_sort | transition of thyroid autoantibodies by rituximab treatment in women with rheumatoid arthritis |
| topic | hashimoto’s thyroiditis autoimmune thyroiditis rituximab |
| url | https://gazimedj.com/articles/transition-of-thyroid-autoantibodies-by-rituximab-treatment-in-women-with-rheumatoid-arthritis/doi/gmj.2024.4237 |
| work_keys_str_mv | AT huseyindemirci transitionofthyroidautoantibodiesbyrituximabtreatmentinwomenwithrheumatoidarthritis AT ebruaydogan transitionofthyroidautoantibodiesbyrituximabtreatmentinwomenwithrheumatoidarthritis AT bilgeceydilek transitionofthyroidautoantibodiesbyrituximabtreatmentinwomenwithrheumatoidarthritis |